Jon Berggren
Stock Analyst at Kepler Capital
(4.25)
# 1,401
Out of 4,476 analysts
72
Total ratings
61.1%
Success rate
18.3%
Average return
Main Sectors:
Stocks Rated by Jon Berggren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0MGB Genmab A/S | Maintained: Hold | kr 2,100 | $1,861.29 | +12.83% | 4 | May 7, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 350.00 | $479.00 | -26.93% | 14 | Apr 29, 2026 | |
| STO: DYVOX Dynavox Group AB (publ) | Maintained: Hold | kr 125.00 → kr 90.00 | $65.30 | +37.83% | 7 | Apr 27, 2026 | |
| FRA: 7XE Nightingale Health Oyj | Maintained: Sell | €1.00 | $0.766 | n/a | 3 | Mar 27, 2025 | |
| AIM: FARN Faron Pharmaceuticals Oy | Maintained: Sell | 77p → 68p | $41.65 | n/a | 4 | Feb 28, 2025 | |
| FRA: 4YL Nanoform Finland Oyj | Maintained: Buy | €3.00 | $0.749 | n/a | 3 | Feb 27, 2025 | |
| LON: 0KFH Revenio Group Oyj | Maintained: Sell | €26.00 | $20.82 | n/a | 5 | Feb 14, 2025 | |
| STO: BACTI.B Bactiguard Holding AB (publ) | Maintained: Hold | kr 35.00 → kr 30.00 | $16.00 | n/a | 4 | Feb 7, 2025 | |
| HUM Humana | Maintained: Hold | $2.59 | $396.75 | n/a | 1 | Apr 4, 2024 | |
| STO: HUM Humana AB (publ) | Maintained: Hold | kr 25.00 | $66.20 | n/a | 14 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 | $1.72 | n/a | 4 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €135.00 | $69.70 | n/a | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €172.00 | $69.80 | n/a | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 640.00 | $176.90 | n/a | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €42.00 | $4.22 | n/a | 2 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €155.00 | $14.80 | n/a | 2 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €105.00 | $75.81 | n/a | 1 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 9,200p | $14,456.00 | n/a | 1 | Dec 17, 2020 |
Genmab A/S
May 7, 2026
Maintained: Hold
Price Target: kr 2,100
Current: $1,861.29
Upside: +12.83%
Swedish Orphan Biovitrum AB (publ)
Apr 29, 2026
Maintained: Buy
Price Target: kr 350.00
Current: $479.00
Upside: -26.93%
Dynavox Group AB (publ)
Apr 27, 2026
Maintained: Hold
Price Target: kr 125.00 → kr 90.00
Current: $65.30
Upside: +37.83%
Nightingale Health Oyj
Mar 27, 2025
Maintained: Sell
Price Target: €1.00
Current: $0.766
Upside: n/a
Faron Pharmaceuticals Oy
Feb 28, 2025
Maintained: Sell
Price Target: 77p → 68p
Current: $41.65
Upside: n/a
Nanoform Finland Oyj
Feb 27, 2025
Maintained: Buy
Price Target: €3.00
Current: $0.749
Upside: n/a
Revenio Group Oyj
Feb 14, 2025
Maintained: Sell
Price Target: €26.00
Current: $20.82
Upside: n/a
Bactiguard Holding AB (publ)
Feb 7, 2025
Maintained: Hold
Price Target: kr 35.00 → kr 30.00
Current: $16.00
Upside: n/a
Humana
Apr 4, 2024
Maintained: Hold
Price Target: $2.59
Current: $396.75
Upside: n/a
Humana AB (publ)
Apr 4, 2024
Maintained: Hold
Price Target: kr 25.00
Current: $66.20
Upside: n/a
Mar 23, 2023
Maintained: Buy
Price Target: $22
Current: $1.72
Upside: n/a
Jan 20, 2022
Maintained: Buy
Price Target: €135.00
Current: $69.70
Upside: n/a
Jan 20, 2022
Maintained: Hold
Price Target: €172.00
Current: $69.80
Upside: n/a
Jan 20, 2022
Maintained: Buy
Price Target: CHF 640.00
Current: $176.90
Upside: n/a
Nov 29, 2021
Maintained: Buy
Price Target: €42.00
Current: $4.22
Upside: n/a
Nov 29, 2021
Maintained: Buy
Price Target: €155.00
Current: $14.80
Upside: n/a
Jun 29, 2021
Maintained: Buy
Price Target: €105.00
Current: $75.81
Upside: n/a
Dec 17, 2020
Maintained: Buy
Price Target: 9,200p
Current: $14,456.00
Upside: n/a